California Public Employees Retirement System Lowers Holdings in DaVita Inc. $DVA

California Public Employees Retirement System reduced its stake in shares of DaVita Inc. (NYSE:DVA) by 16.2% in the 1st quarter, Holdings Channel reports. The fund owned 79,334 shares of the company’s stock after selling 15,322 shares during the period. California Public Employees Retirement System’s holdings in DaVita were worth $12,193,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also bought and sold shares of DVA. Invesco Ltd. lifted its stake in shares of DaVita by 2.0% in the 3rd quarter. Invesco Ltd. now owns 1,679,248 shares of the company’s stock valued at $223,122,000 after purchasing an additional 32,358 shares during the period. Morgan Stanley raised its stake in shares of DaVita by 5.1% during the 4th quarter. Morgan Stanley now owns 1,477,045 shares of the company’s stock worth $167,807,000 after buying an additional 71,156 shares during the period. Arrowstreet Capital Limited Partnership lifted its position in shares of DaVita by 114.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company’s stock valued at $135,196,000 after buying an additional 636,191 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in DaVita by 0.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,089,100 shares of the company’s stock valued at $123,733,000 after acquiring an additional 3,507 shares during the period. Finally, LSV Asset Management raised its position in shares of DaVita by 1.1% during the 4th quarter. LSV Asset Management now owns 936,768 shares of the company’s stock worth $106,426,000 after purchasing an additional 9,739 shares during the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Trading Up 0.5%

DVA stock opened at $235.46 on Friday. The company has a market cap of $15.12 billion, a P/E ratio of 21.84, a P/E/G ratio of 0.77 and a beta of 0.88. The company’s 50-day moving average price is $213.62 and its 200 day moving average price is $168.71. DaVita Inc. has a 52 week low of $101.00 and a 52 week high of $239.64.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, May 5th. The company reported $2.87 EPS for the quarter, topping analysts’ consensus estimates of $2.33 by $0.54. The company had revenue of $3.42 billion for the quarter, compared to the consensus estimate of $3.36 billion. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.DaVita’s quarterly revenue was up 6.0% compared to the same quarter last year. During the same period in the previous year, the business earned $2.00 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, equities research analysts expect that DaVita Inc. will post 15.07 earnings per share for the current year.

Insider Transactions at DaVita

In other news, insider Kathleen Alyce Waters sold 15,405 shares of DaVita stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $208.40, for a total value of $3,210,402.00. Following the transaction, the insider directly owned 109,194 shares of the company’s stock, valued at $22,756,029.60. The trade was a 12.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Joel Ackerman sold 51,471 shares of the business’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $192.10, for a total value of $9,887,579.10. Following the sale, the chief financial officer owned 132,434 shares of the company’s stock, valued at $25,440,571.40. The trade was a 27.99% decrease in their position. The SEC filing for this sale provides additional information. 1.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on DVA shares. UBS Group lifted their price target on DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of DaVita in a research note on Monday, June 8th. Barclays boosted their target price on DaVita from $194.00 to $218.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 8th. Zacks Research lowered shares of DaVita from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Finally, Truist Financial increased their price objective on DaVita from $205.00 to $250.00 and gave the stock a “hold” rating in a research report on Tuesday, July 14th. Two analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $216.50.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.